Mankind Pharma Q1 FY27 Results Analysis: EBITDA Margin Expands 249 bps, PAT Jumps 30%

Mankind Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,030.59 Cr (+12.89% YoY) and PAT growth of +29.12% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Mankind Pharma delivered strong Q1 FY27 results with consolidated revenue growing 12.89% YoY and EBITDA margin expanding 249 bps to 26.30%, driven by operating leverage and lower finance costs. PAT grew 29.60% despite a normalised tax rate. However, no management guidance is available, and the quarter included elevated inventory build-up and ongoing tax proceedings.

Key Investment Insights

Key Positives

• Consolidated revenue grew 12.89% YoY to Rs.4,030.59 crore.
• Consolidated EBITDA margin expanded 249 bps YoY to 26.30%.
• PAT (owners) grew 29.60% YoY to Rs.568.06 crore.
• Finance costs declined 35.55% YoY to Rs.109.98 crore, aided by Rs.1,250 crore NCD redemption.
• Other expenses grew only 8.58% YoY, below revenue growth of 12.89%.
• No exceptional items in Q1 FY27, simplifying earnings comparison.

Risk Factors

• Effective tax rate normalised to 25.39% from 17.74% YoY, reducing net profit growth.
• OCI recorded a net loss of Rs.20.31 crore, driven by negative exchange differences on foreign operations.
• Subsidiary contribution to PAT declined sharply from Rs.23.05 crore in Q1 FY26 to Rs.9.57 crore in Q1 FY27.
• Income tax proceedings of Rs.1,908.66 crore outstanding, with emphasis of matter in audit report.
• Inventory build-up of Rs.133.86 crore (consolidated) indicates working capital investment, likely from BSV integration.